The reiteration of a Buy rating by a reputable analyst like Gil Blum from Needham is likely to instill confidence in investors and could positively influence Gamida Cell's stock price in the short term. The maintained price target of $6 suggests a potential upside from the current trading price, assuming the stock is trading below this target.